Biogen Inc. shares surged more than 18% Friday after the biotechnology company and Tokyo-based Eisai Co. Ltd. announced positive results from a mid-stage trial of a treatment for Alzheimer’s disease, according to a release from MarketWatch.
The final analysis at 18 months of the 856-patient Phase 2 clinical study of BAN2401 in early Alzheimer’s disease demonstrated statistically significant slowing in cognitive decline and reduction of amyloid beta accumulated in the brain, the companies said in a release late Thursday.
Amyloid beta are the protein fragments that are found in the brains of patients suffering from the disease and that some believe cause it.
“New data provide compelling evidence to further support amyloid hypothesis as a therapeutic target for Alzheimer’s disease,” the companies said.
“We will discuss these very encouraging results with regulatory authorities to determine the best path forward,” said Lynn Kramer, chief clinical officer and chief medical officer, neurology, at ESALY, +21.52%
Analysts mostly welcomed the news, especially after earlier data from the trial that proved disappointing.
Read the full story at MarketWatch.